Development and Validation of an HPLC–UV Method for the Analysis of Methoxyamine Using 4-(diethylamino)benzaldehyde as a Derivatizing Agent
Journal of Pharmaceutical and Biomedical Analysis
Methoxyamine (MX) is a potential new anti-cancer drug. In this paper, a quantitative HPLC–UV method for MX using 4-(diethylamino)benzaldehyde (DEAB) as a derivatizing agent has been developed and validated. The studies showed that MX reacts with DEAB under acidic conditions to form protonated 4-(diethylamino)benzaldehyde o-methyloxime (DBMOH+). The equilibrium between DBMOH+ and its conjugate base 4-(diethylamino)benzaldehyde o-methyloxime (DBMO) is affected by both buffer concentration and organic solvent content in the solution. The method developed uses a reversed phase C18 column for the separation of MX derivatives, an internal standard benzil for method calibration, and a UV detector at a wavelength of 310 nm for analyte detection. The MX derivatives can be resolved in ca. 20 min. The method has a linear calibration range from 0.100 to 10.0 μM with a correlation coefficient of 0.999 for MX and a detection limit of 5 pmol with a 50 μl sample size. The intra-assay and inter-assay precision expressed in terms of percent relative standard deviation were ≤5 and 8%; and the intra-assay and inter-assay accuracy defined as the measured value divided by the accepted value multiplied by 100% were 94.2–100 and 92.6–111%, respectively. This method may be used for the analysis of MX in pharmaceutical preparations.
Liao, Y.; Yang, S.; Syu, M.; Xu, Y. Development and validation of an HPLC–UV method for the analysis of methoxyamine using 4-(diethylamino)benzaldehyde as a derivatizing agent. J. Pharm. Biomed. Anal. 2005, 39, 724-729.